GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$41.61 USD
+0.50 (1.22%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $41.62 +0.01 (0.02%) 5:12 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GSK 41.61 +0.50(1.22%)
Will GSK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GSK
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Why the Market Dipped But GSK (GSK) Gained Today
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for GSK
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
UK earnings, trading statements calendar - next 21 days
UK earnings, trading statements calendar - next 7 days
Global company events calendar
Immatics N.V.: An Intriguing Developmental Concern